Fenretinide
4HPR
N-(4-Hydroxyphenyl)-all-trans Retinamide

Orange solid. PROTECT FROM LIGHT. PACKAGED UNDER INERT GAS. A synthetic amide of all-trans retinoic acid (RA) that displays reduced toxicity relative to RA while maintaining significant biological activity. Active in the prevention and treatment of a variety of neoplasms in animals. Inhibits human breast cancer, prostate adenocarcinoma, and ovarian carcinoma cell proliferation. Inhibits angiogenesis as well as endothelial cell motility and tubule formation. Induces apoptosis in malignant hemopoietic cell lines. Purity: ≥97% by TLC. RTECS VH6420000, CAS 65646-68-6.

Merck Index: 14, 3998
Ref.: Formelli, F., et al. 1996. FASEB J. 10, 1014. Naik, H.R., et al. 1995. Adv. Pharmacol. 33, 315. Delia, D., et al. 1993. Cancer Res. 53, 6036. Pienta, K.J., et al. 1993. Cancer Res. 53, 224. Grubbs, C.J., et al. 1990. Anticancer Res. 10, 661. McCarthy, D.J., et al. 1987. Cancer Res. 47, 5014. Moon, R.C., et al. 1979. Cancer Res. 39, 1339.
R: 20/21/22-36/37/38-60-61; S: 26-36/37/39-45